Objectives: To assess the effectiveness of a multivitamin (MV) tablet on nutritional status, quantitative heel ultrasound (QUS), mobility, muscle strength and falls. The design comprised two groups matched on mobility levels, randomized to receive a daily MV or placebo (P) tablet for 6 months. The setting was an Australian residential care facility. Subjects: A total of 92 aged care residents. Serum micronutrients, body weight, QUS, rate of falls, hand grip strength, and the timed up and go test were assessed at baseline and 6 months. Results: A total of 49 participants consumed a MV and 43, a matched P for 6 months. There was a greater increase in the MV vs P group for serum 25(OH)D (mean difference ± standard error, 33.4 ± 2.6 nmol l À1 ), folate (13.4 ± 2.8 nmol l À1 ), and vitamin B12 (178.0±40.3 pmol l À1 ) (all Po0.001). Adequate 25(OH)D concentrations (X50 nmol l À1 ) were found among 77% of participants in the MV group vs 10% taking P (Po0.001). Adjusting for baseline levels, the increase in QUS was greater in the MV vs P group (3.0±2.0 dB MHz À1 vs À2.9±2.1 dB MHz À1 , respectively, P ¼ 0.041). There was a trend towards a 63% lower mean number of falls in the MV vs P group (0.3 ± 0.1 falls vs 0.8 ± 0.3 falls, P ¼ 0.078). Conclusions: MV supplementation raised serum vitamin B12 and folate concentrations and increased serum 25(OH)D, which was accompanied by an apparent positive effect on bone density. We also found a trend towards a reduction in falls and this could contribute to a reduction in fractures.
Introduction
The elderly population in residential care settings have a poor dietary intake (Barr et al., 1984; Nowson et al., 2003; . This may be attributed to a low energy intake, reduced physical activity levels, dementia or depression. Moreover, the elderly have higher daily requirements for nutrients such as protein, calcium and vitamin D compared with younger populations (NHMRC, 2006) . These higher nutritional demands, combined with lower total energy intakes, make it difficult for the elderly to meet the recommended micronutrient intakes from dietary sources alone.
To promote good health, many people worldwide take various forms of multivitamin (MV) supplements (Bender, 2002; Fawzi and Stampfer, 2003) . In elderly community dwellers, daily consumption of a MV/mineral for 2 or 4 months has improved various serum micronutrient concentrations (Mann et al., 1987; McKay et al., 2000a, b) ; however, following 1-year consumption, no reduction in clinical infections or quality of life was found (Avenell et al., 2005) . No studies were found that have documented the impact of a daily MV on functional status (for example, muscle strength and mobility); and to our knowledge, there has been no long-term placebo (P)-controlled, MV supplementation studies among aged care residents who are likely to be at greater risk for nutritional deficiencies and poor functional status.
Some studies however have supplemented elderly groups with one or two nutrients. In a randomized, P-controlled, double-blind trial for 2 years, among Australian aged care residents, vitamin D supplementation (ergocalciferol, initially 250 mg given once weekly and then 25 mg daily) in combination with 600 mg of calcium, reduced the rates of falls (Flicker et al., 2005) ; and among 84-year-old, ambulatory women, supplementation with 20 mg vitamin D 3 and 1200 mg calcium for 18 months, reduced hip fractures by 43% and total non-vertebral fractures by 32% (Chapuy et al., 1992) . In a randomized, double blind, controlled trial, supplementation with folate (5 mg) and vitamin B12 (1500 mg) has been found to reduce hip fracture rates in elderly stroke patients (Sato et al., 2005) . As the elderly appear to be at risk for many micronutrient deficiencies, our aim was to assess the effectiveness of a daily MV for 6 months on nutritional status, bone quality and muscle strength.
Subjects and methods

Study design
The study utilized a double blind, randomized, P-controlled study for 6 months. Initially, it was intended to be a 2 Â 2 factorial design, utilizing fortified milk vs usual milk, where subjects were stratified by mobility for milk allocation; and MV vs P supplementation. The fortified milk was specifically developed by Murray Goulburn Co-operative Ltd, and was designed to contain higher quantities of protein, calcium and vitamin D than usual milk, but similar energy and fat content. However, due to problems with the distribution of the milk to subjects within the facility, the use of fortified milk ceased completely at week 16 of the 6-month study. The use of fortified milk over this short-time period resulted in no significant changes in macro or micronutrient intakes. Importantly, there was no difference in nutrient intake between the P and MV group. Therefore, the following results were analysed between the P and MV group.
All subjects, irrespective of ward/hostel, were randomized (Random number generator, Microsoft Excel, 2002, by CN) to receive the daily MV, which is a readily available off-theshelf MV supplement 'Heron Women's multivitamin', or a placebo tablet (Sigma Company Ltd, Australia) in a double blind fashion. The composition of the MV reflects the labelled content which was confirmed by the manufacturer's assayed composition of the batch used (Table 1) . MV and P tablets were administered by the nursing staff during the morning medication round (0800 hours) with some subjects in low care facilities choosing to self-medicate. The main components of the P were starch maize, cellulose and magnesium stearate.
This project was approved by the Barwon Health Research and Ethics Advisory Committee and Deakin University Human Research Ethics Committee.
Subjects
Subjects were recruited from Barwon Health, Victoria's largest, regional health care provider. It provides 758 inpatient beds; with the Aged Care facility providing 260 high-level care (HLC) nursing home beds and 106 low-level care (LLC) hostel beds. Residents in the dementia, rehabilitation and palliative care wards were excluded from the study. All subjects who were able to consume food orally were eligible to participate in the study (LLC: n ¼ 106; HLC: n ¼ 228).
Study measurements
Information on dietary requirements, mobility levels, medication usage and medical diagnoses were obtained from the medical records. Body weight was measured (monthly) by the nursing staff.
Dietary intake
Dietary intakes were assessed on three separate occasions for a 24 h period (month 2, 4 and 6), where plate waste was visually assessed at all main meals and mid-meals. The aim was to assess each subject once over the study period. Energy and nutrient intakes were calculated using the dietary analysis computer package Food Works, version 4 (Xyris Software; Brisbane, Australia). Values for vitamin D content were added to the database using data from British Food Composition (Paul and Southgate, 1979; Fraser, 1990) .
Falls incidence
Medical diagnosis of osteoporosis and having a history of falls were collected from the medical records at the beginning of the study. For each subject, falls incidence was documented over the 6-month study period by the nursing staff and recorded in the medical history. Medical histories of all subjects were viewed by research staff at the end of the study and the data on falls was extracted.
Anthropometry, QUS and functional status Stature height was calculated by measuring knee height (cm), quantitative heel ultrasound (QUS) was measured using the broadband ultrasonic attenuation value (dB per MHz), the timed up and go test (TUG) and hand grip strength (HGS) were assessed using standard methodological approaches described previously .
Biochemistry
After an overnight fast of at least 8 h, blood samples (10 ml) were collected by venipuncture at baseline and 6 months for measurement of serum albumin, zinc, vitamin B12, folate and 25(OH)D concentrations. Serum albumin was assayed using a Randox Daytona automated clinical chemistry analyzer (Antrim, UK, 2002) . Radioimmunoassays were used to measure serum 25(OH)D (DiaSorin Inc., Stillwater, Minnesota, USA), vitamin B12 and folate (BioRad Laboratories, NSW, Australia) concentrations. The Intra assay CV for 25(OH)D was 8.8%; for vitamin B12 was 13.5% and for folate was 9.2%. Serum zinc was measured using flame atomic absorption spectrophotometry by direct aspiration (Varian SpectrAA-800). The criteria for defining deficiency levels for albumin (Abbasi and Rudman, 1993; Alhamdan, 2004) , 25(OH)D (Diamond et al., 2005) , vitamin B12 (Clarke et al., 2004) , folate (Clarke et al., 2004) and zinc (Pepersack et al., 2001 ) have been described previously.
Compliance
Following tablet consumption, a confirmatory signature was made by the nursing staff in the medication history. Tablet compliance was assessed by researchers at the end of the study by counting the signatures in each subject's medical histories. A total of 10 subjects from LLC were selfmedicated.
Statistical analysis
Statistical analysis was performed using SPSS for Windows (SPSS Inc., Chicago, IL, USA, Release 11.5.2.1). Student's t-tests were used to identify differences in continuous variables between groups. w 2 -tests were used to analyse categorical data. The univariate general linear model was used when comparing absolute and percent changes between the groups over time. Data that was skewed was log 10 transformed (serum folate, 25(OH)D and grip hand strength). Log 10 data was used for all analyses; however, the geometric means were reported in the text.
Results
A total of 122 subjects gave informed consent, or if unable, their next of kin gave proxy consent (Figure 1) . Two subjects withdrew and five died prior to study commencement. A total of 115 subjects commenced the study. There were no differences in baseline characteristics between the MV and P groups ( Table 2) .
Tablet supplementation A total of 57 and 58 subjects were randomly assigned the P and MV tablet, respectively; however, eight subjects were excluded as they were already found to be taking MVs, and two subjects refused to take the MV/P tablet. Withdrawal from the study included seven deaths (four in the P group, three in the MV group); three subjects taking the P suffered side effects (rash/vertigo; behavioral issues and indigestion); and three subjects were transferred to an external facility. Therefore, 49 and 43 subjects completed the study from the MV and P group, respectively. At the end of the study, quantitative heel ultrasound (QUS) could not be measured in 28 subjects: 24 subjects were bed bound, too frail, or could not position their foot correctly and three were non compliant. One subject was excluded from QUS analysis due to abnormally low results (o2.5 s.d. below the mean). Three subjects did not provide serum samples. At the beginning and at the end of the study, seven subjects, each in the P and MV group, took a calcium þ vitamin D supplement; 8 and 12 subjects took a calcium supplement; and four and nine subjects took a vitamin D supplement in the P and MV groups, respectively. The range of daily calcium and vitamin D intake from these supplements was 600-1000 mg and 0.25-25 mg, respectively; this supplement use was maintained throughout the study.
Tablet compliance
Participants consumed on average 82% of the tablets (range: 79-100%) in the P group and 91% (range 76-100%) in the MV group (P40.05). The tablets were consumed for a minimum of 19, and a maximum of 22 weeks.
Dietary intakes
Dietary intake was measured on 39 (80%) subjects in the MV group and 38 (88%) subjects in the P group. There was no difference in dietary intakes between the MV and P groups assessed during the study. The mean (±s.e.m.) daily energy, calcium and folate intakes from dietary sources for the P (n ¼ 38) and MV (n ¼ 39) sample, respectively, were 6.4±0.3 MJ vs 6.8±0.3 MJ; 804±54 mg vs 931±70 mg; and 295±23 mg vs 237±19 mg, all P40.05). The median (inter-quartile) range for vitamin D intake from dietary sources for the P and MV group was 2.1 (0.3) mg vs 2.6 (0.4) mg, respectively.
Nutritional status
At the end of the study, there was a greater rise in the MV group compared to the P group for serum 25(OH)D (33.4. ± 2.6 nmol l À1 ), folate (13.4 ± 2.8 nmol l
À1
) and vitamin B12 (178.0±40.3 pmol l À1 ) (all Po0.001) ( Table 3 ). The percentage differences in serum micronutrients between the groups are illustrated in Figure 2 .
Over the study period, the mean (s.d.) daily vitamin D intake was 9.7 (0.6) mg (range: 6.8-10.0 mg). For those consuming a vitamin D supplement in addition to the MV tablet (n ¼ 10, 21%), the mean (±s.e.m.) vitamin D intake was 30.0±3.9 mg. At the start of the study, those consuming a vitamin D supplement had 77% higher serum 25(OH)D , P40.05). There was an association between baseline serum 25(OH)D and the change in serum 25(OH)D (r ¼ 0.41, Po0.001) where those who had the lowest starting 25(OH)D had the greater rise. When adjusting for baseline serum 25(OH)D concentrations, there was an association between daily vitamin D intake from the MV tablet, and the change in serum 25(OH)D (r ¼ 0.25, P ¼ 0.048). There were no associations between the intake of vitamin B12 or folate from the MV (or additional supplement use) with the changes in serum vitamin B12 or folate, respectively, even when adjusted for baseline serum vitamin B12 and folate.
Serum 25(OH)D concentrations 450 nmol l
À1 were found among 77% of participants in the MV group compared to 10% in the P group (Table 4 ). In the MV group, the prevalence of deficiencies/borderline deficiencies for folate and vitamin B12 after supplementation were lower than that found in the P group at the end of the study (Table 4) . There was an association between the changes in serum 25(OH)D with vitamin B12 (r ¼ 0.28, P ¼ 0.004) and folate (r ¼ 0.37, Po0.001), but no associations between vitamin B12 and folate for absolute values or changes over time. There was no difference in the change in serum zinc between the MV and P group (Table 3) , or for rates of zinc deficiency (o or 410.7 mmol l À1 ) between groups or within groups over time. There was no significant difference in serum albumin (o or 435 g l
À1
) between groups; however, serum albumin fell by 3% in both groups from baseline to the end of the study (Figure 2 ). ).
Body weight
There was no difference in the change in body weight at 6 months between the MV and P groups. In the MV, 34% (n ¼ 15) lost (mean (s.d.) À1.7 (1.4) kg) or gained (1.5 (1.0) kg) 0-5% body weight; and in the P group, 30% (n ¼ 12) lost (À1.3 (0.9) kg) and 32% (n ¼ 13) gained (1.7 (1.2) kg) 0-5% body weight.
Quantitative heel ultrasound and functional status After adjustment for baseline values, the MV group had an improvement in QUS compared to the P group (Figure 3) . This was equivalent to a mean difference between the groups of 5.9±2.8 dB MHz À1 (P ¼ 0.041). The difference in the percentage change however between the MV and P groups was not significant (mean 5 ± 5 vs À2 ± 4%, P ¼ 0.250). At the end of the study, there was an association between serum 25(OH)D and QUS (r ¼ 0.22, P ¼ 0.051), but not between the changes in serum 25(OH)D and QUS. There was no difference in HGS between the MV and P groups at the end of the study; however, there was a mean reduction in HGS where both groups lost 14.5 ± 1.8 kg grip force at 6 months (Table 3 ). There was a negative association between the changes in serum 25(OH)D and HGS (r ¼ À0.29, P ¼ 0.043), and this remained significant when adjusting for baseline weight (P ¼ 0.004), but not weight change. There was a positive association between serum folate and HGS (r ¼ 0.27, P ¼ 0.020).
There was no difference in TUG score between the MV and P groups. Those with serum 25(OH)D levels 450 nmol l À1 at the end of the study had a faster TUG time (n ¼ 13, 21.2±2.0 s) compared with those with serum 25(OH)D p50 nmol l À1 (n ¼ 17, 33.4±4.0 s, P ¼ 0.019). There was a negative association between the changes in serum folate and TUG score (r ¼ À0.32, P ¼ 0.043), indicating the greater the increase in serum folate, the faster the subjects walked during the TUG test. There was a negative association between serum 25(OH)D and TUG score (n ¼ 15, r ¼ À0.46, P ¼ 0.005) after 6 months.
Falls
The one and only Negro subject who fell 24 times (MV group) was excluded from the analyses as a clear outlier.
There was a trend towards a 63% lower mean number of falls in the MV vs P group (0.3 ± 0.1 falls vs 0.8 ± 0.3 falls, P ¼ 0.078). Assessing those that had X1 fall during the study period, there were more falls in the P group compared to the MV group. (n ¼ 12, 2.8 ± 0.6 falls vs n ¼ 11, 1.4 ± 0.2 falls, P ¼ 0.029).
Discussion
Following 6 months of daily MV supplementation, which contained 10 mg vitamin D3, we found an increase in bone quality and a trend towards a 63% lower rate of falls. Although the absolute change in bone quality was significant between the MV and P groups (mean difference: 5.9±2.8 dB MHz
À1
), the percentage change between groups was not significant (MV: þ 5% vs P: À2%). A smaller decrease in QUS of 1.0 dB MHz À1 (1%) was found in a longitudinal study of 88 post-menopausal women over 2 years (Schott et al., 1995) , although our subjects were older and were frail, which may account for the higher rate of bone loss. Similarly, a larger cross-sectional study of 270 female aged care residents observed a nonsignificant decrease of 1% in QUS over 1 year (Krieg et al., 1996) . It appears that our elderly group had a larger rate of bone loss compared with those studies, but it is not clear if this rate of loss would be observed over a longer period of time.
In addition to an indication that MV supplementation increased bone quality, we also found an indication of a reduction in rate of falls, both of which could reduce the risk of fracture. Although the MV contained only 10 mg vitamin D 3 , it also contained 144 mg elemental calcium (360 mg calcium carbonate), plus a range of other micronutrients that may have had a positive effect on bone and risk of falling. A recent study has found a similar reduction in falls over a 5-month period with vitamin D alone, although their dose was twice as that used in our study (Broe et al., 2007) . Further investigations are warranted using a MV supplement over a longer term to confirm these findings in relation to bone quality and rate of falls. ). In Australia, the number of aged care residents with low 25(OH)D levels is high, with estimates ranging between 22 and 74% (Stein et al., 1996; Flicker et al., 2003; . Only one previous study in community dwelling elderly assessed 25(OH)D concentrations following 8 weeks of MV supplementation, which found an increase in serum 25(OH)D of 30%, reducing the rates of serum 25(OH)D levels o37.5 nmol l À1 from 7 to 0% (McKay et al., 2000b) . In that study, however, serum 25(OH)D levels were initially higher (77 nmol l
) compared with our group (36 nmol l
). Other large dose calcium/ vitamin D supplementation studies in elderly residents have not documented rates of 25(OH)D deficiency (Krieg et al., 1999; Peacock et al., 2000; Grados et al., 2003) nor did they measure serum 25(OH)D at follow-up (Flicker et al., 2005; Law et al., 2006) .
The increase in serum vitamin B12 and folate following MV supplementation supports previous studies that assessed the benefit of a single daily MV on nutritional status in community dwelling elderly (Mann et al., 1987; McKay et al., 2000a, b) . We found a greater improvement in the rates of deficiency in the MV group. No other studies have reported serum folate or vitamin B12 levels or deficiency rates in Australian residential care settings, and only few have reported serum folate deficiency rates (8% o6.8 nmol l À1 ; 10% o8.4 nmol l À1 ) (Essama-Tjani et al., 2000; Arinzon et al., 2004) and vitamin B12 deficiency rates (6% o148 pmol l À1 (Dharmarajan et al., 2000) ; 16% o116 pmol l À1 (Huerta et al., 2004) ). As there is no standard cutoff level for these deficiency rates, it is difficult to compare studies, although the folate deficiency rates may have been higher in our study than that reported by others. Limitations to this study included the relatively small sample size which may have reduced the power to detect small differences between the groups; and dietary intakes were assessed on sub-samples at different time points. It should also be acknowledged that the high compliance rate with the tablet consumption may be greater than normally seen among free-living populations; or in residential care settings, where MV administration by staff may be inconsistent.
In conclusion, among our group of Australian aged care residents daily MV consumption for 6 months significantly increased serum 25(OH)D, vitamin B12 and folate concentrations. Daily MV supplementation also appeared to improve bone quality and we found a trend towards a reduction in falls. Further, larger supplementation or fortification studies are warranted with a combination of nutrients, particularly calcium, vitamin D and folate, assessing the effect on bone and muscle function. It is also necessary to assess whether these nutrient combinations result in sustained improvements in bone and muscle function, potentially leading to a significant reduction in falls and fractures among aged care residents.
